$17.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Y-mAbs

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing the therapeutic products for the treatment of cancer. Its product pipeline includes naxitamab and omburtamab. The Company’s lead antibody programs target GD2 and B7-H3. The Company develops naxitamab for the treatment of pediatric patients with relapsed or refractory (R/R), neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system (CNS), leptomeningeal metastases (LM). The Company also creates humanized, affinity matured bispecific antibodies. In addition, the Company has two B7-H3 targeting product candidates, omburtamab- diethylenetriamine pentaacetate (DTPA) and huB7-H3, which are in pre-clinical stage.

Stock Analysis

last close $17.4
1-mo return 2.3%
3-mo return 107.4%
avg daily vol. 266.57T
52-week high 34.6
52-week low 6.5
market cap. $829M
forward pe -
annual div. -
roe -57%
ltg forecast -
dividend yield -
annual rev. $40M
inst own. 70.3%

Subscribe now for daily local and international financial news